Survodutide Hits 16.6% Weight Loss in Phase 3
Survodutide hit 16.6% weight loss in SYNCHRONIZE-1 Phase 3. The Boehringer/Zealand glucagon-GLP-1 dual agonist met both primary endpoints; ADA readout in June.
May 18, 2026 · 2 min read
Boehringer Ingelheim reported positive topline results from SYNCHRONIZE-1, the Phase 3 trial of its glucagon/GLP-1 dual agonist survodutide (BI 456906), on April 28. Adults with obesity treated with survodutide lost an average of 16.6% of body weight at 76 weeks, compared with 3.2% on placebo. The drug met both co-primary endpoints.
What Happened
Survodutide is developed jointly by Boehringer Ingelheim and Zealand Pharma and targets both the glucagon receptor and the GLP-1 receptor — a dual-agonist mechanism that overlaps with the receptor profile of retatrutide, which adds GIP as a third target.
SYNCHRONIZE-1 enrolled 725 adults with obesity or overweight without type 2 diabetes and ran for 76 weeks. Topline results:
- Mean weight loss: 16.6% (efficacy estimand) vs. 3.2% on placebo
- ≥5% weight loss: 85.1% of survodutide-treated participants achieved this threshold
- Body composition: weight reduction was driven predominantly by fat tissue; lean mass contributed a small proportion of the total loss
- Waist circumference: significantly reduced vs. placebo (a pre-specified secondary endpoint)
The trial met its second co-primary endpoint using the treatment-regimen estimand as well, which accounts for all randomized participants regardless of adherence.
Full data, including subgroup analyses and safety tables, will be presented at the American Diabetes Association's 2026 Scientific Sessions in June.
Why It Matters
The GLP-1 competitive landscape has been dominated by Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide, retatrutide, orforglipron). Survodutide represents a third-company entrant into the high-efficacy tier, though its 16.6% result trails the 20–24% range seen in tirzepatide's SURMOUNT-1 and retatrutide's Phase 2 and Phase 3 TRIUMPH data.
FierceBiotech noted that the SYNCHRONIZE-1 readout "leaves key questions unanswered," including the full safety profile and how survodutide's lean-mass-sparing effect compares across the class. The predominantly fat-driven weight loss finding is notable — it's the first Phase 3 data for any approved or late-stage GLP-1 compound to report this distinction as a primary analysis component, rather than a post-hoc.
Glucagon/GLP-1 dual agonism is a mechanism shared in part with retatrutide's triple-agonist design. The comparative data — survodutide at 16.6% vs. retatrutide's 24% — suggests the GIP receptor arm in retatrutide adds meaningful incremental efficacy to glucagon + GLP-1 alone.
What to Watch
Full data at ADA 2026 (June) will clarify safety, dose-response, and how the compound performs in diabetic populations. Boehringer Ingelheim has not announced a regulatory submission timeline; an NDA would likely follow later in 2026 or early 2027. For context on where survodutide sits in the next-generation pipeline, see the retatrutide overview and tirzepatide complete guide.
Sources
Sources